A5090062651- Peripheral Neuropathies and Disorders
- Inflammatory Myopathies and Dermatomyositis
- Autoimmune Neurological Disorders and Treatments
- Myasthenia Gravis and Thymoma
- Hereditary Neurological Disorders
- Eosinophilic Disorders and Syndromes
- Genetic Neurodegenerative Diseases
- Muscle Physiology and Disorders
- Viral Infections and Immunology Research
- Neurogenetic and Muscular Disorders Research
- Immunodeficiency and Autoimmune Disorders
- Multiple Sclerosis Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Skin Diseases and Diabetes
- Muscle and Compartmental Disorders
- Ion channel regulation and function
- Peripheral Nerve Disorders
- Parkinson's Disease and Spinal Disorders
- Cardiomyopathy and Myosin Studies
- Chronic Lymphocytic Leukemia Research
- Systemic Lupus Erythematosus Research
- Neurological disorders and treatments
- Botulinum Toxin and Related Neurological Disorders
- Long-Term Effects of COVID-19
- Skin and Cellular Biology Research
National and Kapodistrian University of Athens
2016-2025
Thomas Jefferson University
2016-2025
University of California, San Francisco
2020-2023
Universitat de Barcelona
2019-2023
Institució Catalana de Recerca i Estudis Avançats
2020-2023
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2020-2023
University of Pennsylvania
2013-2023
National Institutes of Health
2002-2022
National Institute of Neurological Disorders and Stroke
2003-2022
Harvard University
2022
Dermatomyositis is a clinically distinct myopathy characterized by rash and complement-mediated microangiopathy that results in the destruction of muscle fibers. In some patients condition becomes resistant to therapy causes severe physical disabilities.
The IIM are a heterogeneous group of systemic rheumatic diseases which share the common features chronic muscle weakness and mononuclear cell infiltrates in muscle. A number classification schemes have been proposed for them, but none takes into consideration marked immunologic, clinical, genetic heterogeneity various clinical groups. We compared usefulness myositis-specific autoantibodies (anti-aminoacyl-tRNA synthetases, anti-SRP, anti-Mi-2 anti-MAS) to standard categories (polymyositis,...
Both infection with the human immunodeficiency virus type 1 (HIV) and zidovudine (formerly called azidothymidine [AZT]) cause myopathy. To identify criteria for distinguishing zidovudine-induced myopathy from that caused by primary HIV infection, we reviewed histochemical, immunocytochemical, electron-microscopical features of muscle-biopsy specimens 20 HIV-positive patients (15 whom had been treated zidovudine) compared findings patients' clinical course response to various therapies. Among...
Objectives To develop recommendations for the diagnosis, prevention and treatment of neuropsychiatric systemic lupus erythematosus (NPSLE) manifestations. Methods The authors compiled questions on prevalence risk factors, diagnosis monitoring, therapy prognosis NPSLE. A systematic literature search was performed evidence categorised based sample size study design. Results Systemic (SLE) patients are at increased several Common (cumulative incidence >5%) manifestations include...
This multicenter, randomized, double-blind, crossover trial compared a six week course of oral prednisolone tapering from 60 mg to 10 daily with intravenous immunoglobulin (IVIg) 2.0 g/kg given over one two days for treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Twenty-four the thirty-two randomized patients completed both treatment periods. Both treatments produced significant improvements in primary outcome measure, change an 11-point disability scale weeks...
Long-term zidovudine therapy in patients with human immunodeficiency virus (HIV) infection can cause a destructive mitochondrial myopathy histological features of ragged-red fibres (RRF) and proliferation abnormal mitochondria. In 9 zidovudine-treated this we found severely reduced amounts (up to 78% reduction vs normal adult controls) DNA (mtDNA) muscle biopsy specimens by means Southern blotting. 2 HIV-positive who had not received zidovudine, mtDNA content did differ from that the 4...
Stiff-person syndrome is a disabling central nervous system disorder with no satisfactory treatment that characterized by muscle rigidity, episodic spasms, high titers of antibodies against glutamic acid decarboxylase (GAD65), and frequent association autoimmune disorders. Because stiff-person most likely immune-mediated, we evaluated the efficacy intravenous immune globulin.
In patients with dermatomyositis (DM) the earliest lesion is microvasculopathy mediated by deposition of C5b-C9 membranolytic attack complex (MAC) on intramuscular capillaries. This leads sequentially to muscle ischemia, necrosis fibers, and weakness. High-dose intravenous immunoglobulin (IVIG), which can modulate complement-dependent tissue damage in animal models, has been shown be effective treatment DM. We used an vitro C3 uptake assay examine 55 coded sera from 13 DM 5 other...
A "post-polio" syndrome characterized by new neuromuscular symptoms, including muscle weakness, may develop years after recovery from acute paralytic poliomyelitis. We studied 27 patients (mean age, 50.6 years) in whom weakness developed a mean of 28.8 polio. reevaluated these during follow-up period 8.2 (range, 4.5 to 20) they were originally at the National Institutes Health. The total onset was 12.2 6 29). assessed with quantitative testing, biopsy, electromyography, and virologic...
Abstract Objective Report a double‐blind, placebo‐controlled study of rituximab in patients with anti–MAG demyelinating polyneuropathy (A‐MAG‐DP). Methods Twenty‐six were randomized to four weekly infusions 375mg/m 2 or placebo. Sample size was calculated detect changes ≥1 Inflammatory Neuropathy Course and Treatment (INCAT) leg disability scores at month 8. IgM levels, anti‐MAG titers, B cells, antigen‐presenting immunoregulatory T cells monitored every months. Results Thirteen A‐MAG‐DP 13...
IgG molecules exert both pro- and antiinflammatory effector functions based on the composition of fragment crystallizable (Fc) domain glycan. Sialylated Fc domains have properties that are attributed to their ability increase activation threshold innate cells immune complexes by stimulating upregulation inhibitory Fcγ receptor IIB (FcγRIIB). Here, we report sialylation human monoclonal IgG1 impairs efficacy induce complement-mediated cytotoxicity (CDC). a CD20-targeting antibody had no...
Recovery from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection appears exponential, leaving a tail of patients reporting various long COVID symptoms including unexplained fatigue/exertional intolerance and dysautonomic sensory concerns. Indirect evidence links to incident polyneuropathy affecting the small-fiber (sensory/autonomic) axons.We analyzed cross-sectional longitudinal data with World Health Organization (WHO)-defined without prior neuropathy history or risks...
Established EG7 tumors expressing OVA and growing at an intradermal site become rapidly reduced in size following adoptive therapy with vitro-generated type I CD8 T cell (Tc1) effectors generated from naive cells transgenic TCR OVA-specific mice. Tc1 kill target vitro by a perforin-dependent mechanism. However, we show that there is no quantitative diminution of the initial phase antitumor activity vivo, whether are derived perforin-, Fas ligand-, or TNF-deficient mice recipients perforin...